Patrick Arensdorf

Tethys Bioscience was dedicated to the discovery, development and commercialization of novel biological markers biomarkers that provided a practical tool to address the growing global challenge of chronic metabolic diseases such as diabetes. By developing new tests that used protein and other blood borne biomarkers to identify people at high risk for devastating and preventable diseases, they can arm patients and physicians with knowledge they can use to help prevent disease progression. These biomarkers gave a snapshot of an individual's current risk, which may be modifiable. Their goal was to provide clinicians with an objective and convenient means to risk-stratify their patients and help them focus appropriate intervention strategies on those most likely to benefit. Their research strategies lead to sets of biomarkers that can be used to quantify the level of an individual's risk. The company had become a pioneer in the discovery, development and value creation of novel biological markers for the clinical diagnostics marketplace: The company had built expertise, created significant intellectual property, and was executing its business plan around three key areas: Biomarker Discovery, Clinical Validation and ValueCreation. It was focused upon introducing products that yield significant savings to the health care system and improve the quality of life for patients.

First Medical Group, Inc. owns and operates medical clinics in Eastern Europe and its medical centres provide healthcare services to expatriates and other local nationals. The company was founded in 1997 and is headquartered in Kapolei, HI.

Critical Care Diagnostics, Inc. develops diagnostic tools. The firm offers Presage, a laboratory assay employing ST2 for the diagnosis and prognosis of cardiovascular disease. It also offers Aspect-PLUS ST2 test, a cardiac biomarker testing product that aids clinicians in assessing risk, making treatment decisions, evaluating therapy effectiveness, and monitoring patient care. The company was founded by Sven M. Jacobson and David M. Geliebter in 2004 and is headquartered in San Diego, CA.

Intersect ENT, Inc. is a commercial drug delivery company, which engages in the treatment of ear, nose, and throat conditions. Its products include PROPEL and SINUVA. The PROPEL used to maintain the opening and locally deliver steroid after sinus surgery. The SINUVA is used to treat adult patients with ethmoid sinus surgery yet suffer from recurrent sinus obstruction due to polyps. The company was founded by Donald J. Eaton in October 2003 and is headquartered in Menlo Park, CA.

Empirical Spine, Inc. develops minimally invasive, flexion-restricting stabilization devices for the spine. It offers LimiFlex Spinal Stabilization System which is a novel implant that provides segmental stability to the lumbar spine while still allowing motion and also used in conjunction with a surgical decompression for the treatment of lumbar spinal stenosis with or without degenerative spondylolisthesis. The company was founded by Louis Fielding, John Colin Cahill, Ian Bennett and Todd F. Alamin in 2006 and is headquartered in San Carlos, CA.

Diadexus, Inc. engages in the research, development, and commercialization of pharmaceutical products. Its portfolio intends to treat cardiovascular diseases. The company was founded on November 27, 1995 and is headquartered in South San Francisco, CA.

Exai Bio, Inc. is an American next-generation liquid biopsy company founded by Hani Goodarzi, Babak Alipanahi, and Patrick Arensdorf. The company's mission is to enable early detection, accurate diagnosis, personalized and targeted treatment, and ultimately cure of cancer. Exai Bio's proprietary RNA- and AI-based liquid biopsy technology delivers clinical insights into cancer biology to enable the earliest and most accurate diagnosis of cancer. Patrick Arensdorf has been the CEO since incorporation.